68Ga-BCMA PET/CT in Multiple Myeloma

Summary

This is a prospective, multicenter diagnostic imaging study designed to evaluate the diagnostic accuracy and clinical utility of BCMA-targeted positron emission tomography/computed tomography (PET/CT) in patients with multiple myeloma and related plasma cell disorders. The study aims to non-invasively visualize and quantify whole-body BCMA expression and to assess its role in the detection of active disease and disease heterogeneity.

Eligibility

Inclusion Criteria:

* patients with suspected or previously diagnosed multiple myeloma (MM) who were scheduled for bone marrow aspiration or tissue biopsy within two weeks, including those undergoing initial diagnostic evaluation or follow-up/re-evaluation for disease monitoring or relapse;
* patients with confirmed symptomatic MM;
* ability to understand and voluntarily sign written informed consent;
* ability to comply with study procedures;
* Eastern Cooperative Oncology Group (ECOG) performance status ≤2.

Exclusion Criteria:

* pregnancy or lactation;
* inability to comprehend study procedures or cooperate with protocol requirements;
* any other condition judged by the investigator to potentially interfere with study participation.

Conditions4

Browse More Trials